Personalis バランスシートの健全性
財務の健全性 基準チェック /56
Personalisの総株主資本は$254.8M 、総負債は$879.0Kで、負債比率は0.3%となります。総資産と総負債はそれぞれ$325.4Mと$70.6Mです。
主要情報
0.34%
負債資本比率
US$879.00k
負債
| インタレスト・カバレッジ・レシオ | n/a |
| 現金 | US$233.22m |
| エクイティ | US$254.77m |
| 負債合計 | US$70.63m |
| 総資産 | US$325.40m |
財務の健全性に関する最新情報
分析記事 • Sep 10
Is Personalis (NASDAQ:PSNL) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Dec 04
Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Recent updates
ナラティブの更新 • Jun 19
PSNL: Recent Coverage, Clinical Progress And Losses Will Shape Longer Term Upside
Analysts have reduced their price targets on Personalis stock by about $1 to $2, citing updated fair value estimates near $9.00, an adjusted discount rate, and refreshed assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary on Personalis Stock Recent research updates around Personalis reflect a more cautious tone, with price targets trimmed by about $1 to $2 as bearish analysts reassess valuation and execution risks.分析記事 • Jun 16
Personalis (PSNL) Stock Could Be 10% Undervalued After ASCO Cancer Data
Personalis (PSNL) stock is in focus after the company released new clinical data at the 2026 ASCO meeting, highlighting how its NeXT Personal test detects minimal residual disease across six solid tumor types. See our latest analysis for Personalis. The ASCO update comes after a sharp 53.93% 1 month share price return and a 37.50% 3 month share price return. The 1 year total shareholder return of 51.78% and very large 3 year total shareholder return indicate that momentum has been strong...
ナラティブの更新 • Jun 04
PSNL: Ultrasensitive MRD Evidence And Expanded Coverage Will Support Balanced Future Outlook
Analysts have trimmed their price targets on Personalis by $1 to $2, citing updated assumptions for discount rates, profit margins, and long term P/E expectations. These revisions result in a slightly lower overall valuation outlook.Seeking Alpha • May 28
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating
Summary Personalis, Inc. is rated Buy, driven by strong momentum in its NeXT Personal Dx MRD test and recent Medicare coverage expansions. Despite a projected 2026 net loss of ~$100m and 14% revenue growth, PSNL's clinical test volume is ramping rapidly, with 43k–45k tests targeted this year. Key catalysts include expanded CMS MolDX coverage for breast and lung cancer recurrence monitoring and potential M&A interest given an $887m market cap. Risks include reliance on major pharma clients, a competitive MRD landscape, and the need to prove durable, scalable revenue growth amid ongoing losses. Read the full article on Seeking Alphaナラティブの更新 • May 21
PSNL: Expanded Coverage And MRD Evidence Will Underpin Future Upside Potential
Analysts have nudged their average price target for Personalis lower by about $0.40. This reflects updated forecasts that factor in higher projected net losses and operating expenses in later years.ナラティブの更新 • May 01
PSNL: Medicare Coverage And MRD Data Will Support Future Upside Potential
Analysts have trimmed their price target on Personalis to $10 from $11, citing updated views on longer term operating expenses and expected net losses. These updates also feed into a slightly higher discount rate and future P/E assumptions in current models.ナラティブの更新 • Apr 16
PSNL: Higher Spending And 2026 Loss Will Set Up Longer Term Upside Potential
Analysts now converge around a $10 price target for Personalis, reflecting updated views that incorporate expectations for higher outer year operating expenses and a wider 2026 net loss. Analyst Commentary Recent research updates point to a more cautious tone around Personalis, particularly as analysts factor in guidance for higher operating expenses and a wider 2026 net loss.ナラティブの更新 • Apr 02
PSNL: Expanded Clinical Evidence And Coverage Will Support A Stronger Long Term Outlook
Analysts now center on a $10 price target for Personalis, citing updated loss expectations and higher longer term operating expense assumptions as key drivers of the shift from prior Street estimates. Analyst Commentary Bearish analysts are resetting expectations around Personalis, using the new $10 price target as a reference point for what they see as a more cautious risk and reward profile.
ナラティブの更新 • Mar 19
PSNL: Medicare Coverage And MRD Data Will Reprice Future Risk Reward
Analysts have adjusted their view on Personalis, with price targets now ranging between $10 and $11 as they factor in updated expectations for future losses and operating expenses. Analyst Commentary Recent research updates on Personalis highlight a mix of cautious modeling changes and ongoing interest in the company’s longer term potential.ナラティブの更新 • Mar 05
PSNL: Medicare Coverage Will Support Future Risk Reward Repricing
Narrative Update on Personalis The analyst price target on Personalis has moved from $13 to $13.00 as analysts factor in updated assumptions around revenue growth, profit margin and future P/E expectations. Analyst Commentary Bullish analysts have adjusted their price targets on Personalis, with one recent move taking the target to $13.00.ナラティブの更新 • Feb 18
PSNL: Medicare Coverage And Refined Assumptions Will Support A Brighter Outlook
Analysts have increased their price target on Personalis by $1, citing updated views on fair value, slightly revised discount rate assumptions, and refreshed expectations for revenue growth, profit margin, and future P/E. Analyst Commentary Although the latest research includes a higher price target for Personalis, the tone around the stock remains measured.ナラティブの更新 • Feb 04
PSNL: Medicare Coverage For Cancer Surveillance Will Reshape Future Risk Reward Profile
Analysts have increased their fair value estimate for Personalis from US$9.00 to US$13.00, citing updated assumptions around revenue growth, profit margins, and future P/E. They have also incorporated recent Street research that reflected Medicare coverage news and refreshed price targets.ナラティブの更新 • Jan 21
PSNL: Medicare Coverage Will Shape Future Upside Despite Biopharma Headwinds
Narrative update on Personalis Analysts have lifted their blended price expectations for Personalis toward the US$9 to US$11 range, citing recent Medicare coverage for the NeXT Personal test and Q3 revenue that came in above guidance as key supports for the higher targets. Analyst Commentary Recent Street research on Personalis has focused on two main developments: Medicare coverage for the NeXT Personal test in breast cancer surveillance, and Q3 revenue that came in ahead of the guided range, internal estimates, and consensus.分析記事 • Jan 17
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Personalis, Inc. ( NASDAQ:PSNL ) shares have had a really impressive month, gaining 28% after a shaky period...ナラティブの更新 • Jan 07
PSNL: Medicare Coverage And Biopharma Headwinds Will Shape A Balanced Outlook
Analysts lifted their projected fair value for Personalis, citing recent price target increases to $9 and $11, and pointing to Medicare coverage for the NeXT Personal test and reimbursement trends as key supports for their updated view. Analyst Commentary Recent research takes a mixed view on Personalis, with price targets being adjusted around specific catalysts such as Medicare coverage for NeXT Personal and reported Q3 revenue.ナラティブの更新 • Dec 23
PSNL: Medicare Coverage Will Drive Reimbursement Momentum And Support A Higher Share Price
Analysts have raised their price target on Personalis significantly, from about $5 to a range centered near $10 per share, citing stronger revenue growth expectations, improving profit margins, and increased confidence in long-term reimbursement trends. Analyst Commentary Recent target price revisions reflect a more constructive outlook on Personalis as reimbursement visibility improves and revenue trends modestly outperform prior expectations.ナラティブの更新 • Dec 09
PSNL: Medicare Reimbursement Will Drive Future Momentum Despite Biopharma Guidance Headwinds
Analysts have modestly raised their price target on Personalis, citing stronger-than-expected Q3 revenue and expanding reimbursement visibility. Their estimate of fair value has edged up from roughly $10.71 to $11.00 per share.ナラティブの更新 • Nov 24
PSNL: Medicare Coverage Will Support Momentum Despite Guidance Headwinds
Narrative Update on Personalis Analysts have raised their price target for Personalis from approximately $8.50 to $10.71 per share. They cite recent Medicare coverage for the NeXT Personal test and stronger-than-expected quarterly revenue as supporting factors for the upward revision.ナラティブの更新 • Nov 08
PSNL: Reimbursement Progress Will Drive Momentum Despite Guidance Reduction
Analysts have raised their fair value estimate for Personalis from $8.06 to $8.50 per share. They cite stronger revenue growth prospects and continued progress on reimbursement as key factors behind the upgrade.分析記事 • Nov 07
Personalis, Inc. (NASDAQ:PSNL) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.50
Personalis, Inc. ( NASDAQ:PSNL ) just released its quarterly report and things are looking bullish. Revenues beat...分析記事 • Oct 31
Personalis, Inc.'s (NASDAQ:PSNL) P/S Is Still On The Mark Following 46% Share Price Bounce
Despite an already strong run, Personalis, Inc. ( NASDAQ:PSNL ) shares have been powering on, with a gain of 46% in the...ナラティブの更新 • Oct 25
Clinical Testing Progress And Medicare Coverage Will Influence Share Momentum Ahead
Analysts have revised Personalis's price target downward from $8.00 to $6.00. They cite weaker than expected pharma order timing and softer profit projections, despite continued progress in clinical testing and Medicare coverage goals.分析記事 • Sep 16
Revenues Tell The Story For Personalis, Inc. (NASDAQ:PSNL) As Its Stock Soars 29%
Personalis, Inc. ( NASDAQ:PSNL ) shareholders are no doubt pleased to see that the share price has bounced 29% in the...分析記事 • Sep 10
Is Personalis (NASDAQ:PSNL) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 10
These Analysts Think Personalis, Inc.'s (NASDAQ:PSNL) Sales Are Under Threat
Today is shaping up negative for Personalis, Inc. ( NASDAQ:PSNL ) shareholders, with the analysts delivering a...分析記事 • Aug 02
Personalis, Inc. (NASDAQ:PSNL) Stocks Pounded By 28% But Not Lagging Industry On Growth Or Pricing
The Personalis, Inc. ( NASDAQ:PSNL ) share price has softened a substantial 28% over the previous 30 days, handing back...分析記事 • May 06
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 37% But Its P/S Still Looks Reasonable
Personalis, Inc. ( NASDAQ:PSNL ) shareholders are no doubt pleased to see that the share price has bounced 37% in the...
新しいナラティブ • Mar 30
NeXT Personal Testing And Moderna Partnership Will Improve Cancer Care
Strategic partnerships and agreements are expected to drive significant revenue and market expansion, particularly in MRD testing and tumor profiling.分析記事 • Mar 21
What You Can Learn From Personalis, Inc.'s (NASDAQ:PSNL) P/S After Its 40% Share Price Crash
Personalis, Inc. ( NASDAQ:PSNL ) shareholders that were waiting for something to happen have been dealt a blow with a...分析記事 • Mar 02
Personalis, Inc. (NASDAQ:PSNL) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a sad week for Personalis, Inc. ( NASDAQ:PSNL ), who've watched their investment drop 12% to US$4.14 in the...分析記事 • Feb 04
Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Personalis, Inc. ( NASDAQ:PSNL ) shares have had a horrible month, losing 26% after a relatively good period...分析記事 • Nov 19
Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Personalis, Inc. ( NASDAQ:PSNL ) share price has dived 26% in the last thirty...Seeking Alpha • Oct 28
The Proper Play On Personalis
Summary Today, we revisit the diagnostic concern of Personalis, Inc. The company recently expanded its partnership with Tempus AI and is seeing lower quarterly losses. The company has a solid balance sheet, strong analyst support, and is seeing revenue growth in a large and growing market. An updated analysis around Personalis follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • Sep 14
Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump
Personalis, Inc. ( NASDAQ:PSNL ) shares have continued their recent momentum with a 28% gain in the last month alone...分析記事 • Jul 25
A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb
Personalis, Inc. ( NASDAQ:PSNL ) shareholders have had their patience rewarded with a 131% share price jump in the last...分析記事 • Apr 19
Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower
Personalis, Inc. ( NASDAQ:PSNL ) shares have had a horrible month, losing 25% after a relatively good period...分析記事 • Mar 02
Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story
Personalis, Inc. ( NASDAQ:PSNL ) shareholders would be excited to see that the share price has had a great month...分析記事 • Dec 18
Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story
Personalis, Inc. ( NASDAQ:PSNL ) shareholders would be excited to see that the share price has had a great month...分析記事 • Dec 04
Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...財務状況分析
短期負債: PSNLの 短期資産 ( $258.2M ) が 短期負債 ( $39.0M ) を超えています。
長期負債: PSNLの短期資産 ( $258.2M ) が 長期負債 ( $31.6M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: PSNL総負債よりも多くの現金を保有しています。
負債の削減: PSNLの負債対資本比率は、過去 5 年間で0%から0.3%に増加しました。
貸借対照表
キャッシュ・ランウェイ分析
過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。
安定したキャッシュランウェイ: PSNLは、現在の フリーキャッシュフロー に基づき、1 年以上にわたって十分な キャッシュランウェイ を有しています。
キャッシュランウェイの予測: PSNLは、フリー キャッシュ フローが毎年3.4 % の歴史的率で減少し続ける場合、 2.5年間十分なキャッシュ ランウェイを有しています。
健全な企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/20 16:55 |
| 終値 | 2026/06/18 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Personalis, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13
| アナリスト | 機関 |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| Patrick Donnelly | Citigroup Inc |